Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06598306
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-13
Brief Title:
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer DeLLphi-308
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer DeLLphi-308
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DeLLphi-308
Brief Summary:
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous SC tarlatamab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None